We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.20 | 3.03% | 40.76 | 40.59 | 40.80 | 40.80 | 40.12 | 40.15 | 2,775,124 | 22:20:00 |
From Jul 2023 to Jul 2024
By Giulia Petroni
Roche said the U.K.'s medicines regulator has approved its Tecentriq intravenous cancer therapy.
The Swiss pharmaceutical company said Tuesday that the therapy will be available to patients for all indications in which the formulation has been previously approved, including certain types of lung, bladder, breast and liver cancer.
Tecentriq SC is Roche's fourth subcutaneous cancer therapy.
The approval granted by the U.K. Medicines and Healthcare products Regulatory Agency is the first for Tecentriq SC globally. Evaluations by the U.S. Food and Drug Administration and other health authorities are currently underway, Roche said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
August 29, 2023 05:36 ET (09:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
